Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial - NBC News — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Moderna and Merck co-developed a personalized mRNA vaccine that cut the risk of melanoma recurrence by over 40% in a phase 2b trial, according to results reported by NBC News and WIRED.
- Moderna stock declined following the trial announcement, extending losses as investors weighed the clinical success against earlier expectations, per the Wall Street Journal.
- The vaccine targets melanoma patients with high risk of recurrence after surgical removal of tumors, using mRNA technology to train the immune system to recognize patient-specific cancer mutations.
- Trial data showed a statistically significant improvement in recurrence-free survival, positioning the treatment as a potential new standard for adjuvant therapy in advanced skin cancer.
Why it matters: Patients with late-stage melanoma gain a promising new tool to prevent cancer return, while Moderna faces investor skepticism despite positive trial results—highlighting a disconnect between clinical progress and market valuation. The 40% reduction in recurrence risk is a measurable advance in oncology, but stock movement suggests expectations had outpaced near-term deliverables.
Ask SkimNews
